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Abstract
Background/Aim: To evaluate three mitral bioprostheses (of comparable measured
internal diameters) under controlled, stable, hemodynamic and surgical conditions by
bench, echocardiographic, computerized tomography and autopsy comparisons pre‐
and postvalve implantation.
Methods: Fifteen similar‐sized Yorkshire pigs underwent preprocedural computerized
tomography anatomic screening. Of these, 12 had consistent anatomic features and
underwent implantation of a mitral bioprosthesis via thoracotomy on cardiopulmonary
bypass (CPB). Four valves from each of three manufacturers were implanted in randomized fashion: 27‐mm Epic, 27‐mm Mosaic, and 25‐mm Mitris bioprostheses. After CPB,
epicardial echocardiographic studies were performed to assess hemodynamic function
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and define any paravalvular leaks, followed by postoperative gated contrast computerized
tomography. After euthanasia, animals underwent necropsy for anatomic evaluation.
Results: All 12 animals had successful valve implantation with no study deaths. Postoperative echocardiographic trans‐valve gradients varied among bioprosthesis manu-

Funding information

facturers. The 25‐mm Mitris (5.1 ± 2.7)/(2.6 ± 1.3 torr) had the lowest peak/mean gradient

Edwards Lifesciences Corp to Synchrony Labs

and the 27‐mm Epic bioprosthesis had the highest (9.2 ± 3.7)/(4.6 ± 1.9 torr). Surgical
valve opening area (SOA) varied with the 25‐mm Mitris having the largest SOA
(2.4 ± 0.15 cm2) followed by the 27‐mm Mosaic (2.04 ± 0.23 cm2) and the 27‐mm Epic
(1.8 ± 0.27 cm2) valve. Bench device orthogonal internal diameter measurements did not
match manufacturer device size labeling: 25‐mm Mitris (23 × 23 mm), 27‐mm Mosaic
(23 × 22 mm), 27‐mm Epic (21 × 21 mm).
Conclusions: Current advertisement/packaging of commercial surgical mitral valves
is not uniform. This study demonstrates marked variations in hemodynamics, valve
opening area and anatomic dimensions between similar sized mitral bioprostheses.
These data suggest a critical need for standardization and close scientific evaluation
of surgical mitral bioprostheses to ensure optimal clinical outcomes.

This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium,
provided the original work is properly cited.
© 2021 The Authors. Journal of Cardiac Surgery published by Wiley Periodicals LLC
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1

| INTRODUCTION

preparation of the manuscript. Study design, evaluation, and implementation was performed by the Cardiovascular Masters Con-

Surgical valve design has undergone many iterations since 1952,

sortium, LLC (CMC). The CMC is an independent group of established

when Charles Hufnagel implanted the first surgical valve, to treat

physicians in the fields of cardiac surgery and cardiac intervention

aortic insufficiency.1 Valve design has evolved to include develop-

who objectively assess new cardiovascular technologies using sci-

ment of mechanical, bioprosthetic, and ultimately rapid‐deployment

entifically designed preclinical and clinical studies. The study protocol

aortic valves for minimally‐invasive approaches. There have also been

was approved by the Institutional Animal Care and Use Committee of

major advances in the reduced need for anticoagulation, improved

Synchrony Labs (Synchrony Labs LLC, Durham, North Carolina) and

hemodynamic performance, and management of patient‐prosthesis

all animals received humane care in compliance with the Guide for the

mismatch. However, as designs have evolved to tackle these chal-

Care and Use of Laboratory Animals.5

lenges, there has been a lack of direct‐independent scientific comparison of the various bioprosthetic designs.

Primary endpoints were defined according to the Mitral Valve
Academic Research Consortium criteria for technical, device, and

There is little literature on outcomes of long‐term surgical bio-

procedural success.6 Secondary endpoints evaluated specific device‐

prosthetic mitral valves with regard to echocardiographic gradients,

related technical failure and complications. This included presence or

surgical valve true‐annular opening, and true risk of left ventricular

absence of any paravalvular leak, device positioning, surgical valve

outflow tract (LVOT) obstruction. The literature on surgical mitral

opening area (SOA) and bioprosthesis impact on LVOT obstruction

rings and prosthetic heart valves suggests that manufacturer‐labeled

(gradient increase ≥10 torr from baseline).6 SOA was obtained ac-

dimensions for surgical mitral bioprostheses are not rooted in sci-

cording to traditional mitral valve leaflet tip area planimetry7; defined

2–4

entific data.

Inconsistent definitions of prosthesis labeled sizing,

as the maximal leaflet opening area of the mitral bioprosthesis leaflet

inconsistences between sizer dimensions and manufacturer labeled

tips that corresponded to the largest effective surgical leaflet opening

valve sizing are complex issues identified by the Valve Labelling Task

area of the mitral bioprosthesis, obtained on parasternal short axis

Force necessitating important regulatory evaluation.3 Surgical pros-

views by echocardiographic and multiplanar 3D computed tomo-

3

thesis valve sizing and device selection remain not well understood.
Surgical

mitral

bioprosthetic

implantation

technique

graphy (CT) analysis.

and

manufacturer‐issued labeling of device instructions for use vary
among vendors. No recent controlled study has evaluated the acute

2.2 |

Animal preparation and examination

safety, durability, and function of current surgical mitral bioprostheses in a head‐to‐head comparison study. In human clinical

Before procedural consideration, all animals underwent anatomical

trials, this is not feasible due to wide variations in patient‐specific

evaluation with multidetector contrast‐enhanced electrocardio-

hemodynamic conditions and anatomy, as well as the absence of

graphic (ECG) gated CT scanning, using an on‐site Siemens scanner

autopsy verification of in‐situ comparative measurements. This pre-

(Siemens Dual Somatom, Siemens Medical, Forchheim, Germany).1,8

clinical early feasibility experimental study evaluates three surgical

Preprocedural screening looked specifically at anatomical character-

mitral bioprostheses of comparable measured internal diameters in a

istics that would be used by a physician in the clinical setting. These

head‐to‐head study of acute mitral bioprosthetic valve function

data focused on evaluation of subjects' mitral annulus size during

postimplantation in the setting of controlled anatomical sizing, he-

maximal diastolic dimensions, left atrial size and trans‐septal catheter

modynamic variables, and surgical expertise.

crossing height at mid‐end systole. Those with transseptal crossing
heights (defined as potential mid‐mid transseptal fossa puncture to
mitral annulus distance) ≤15 mm or mitral annulus dimensions (by

2

| MATERIALS AND METHODS

diameters, area, or perimeter) with greater than 6% variation from
other study animals were excluded from enrollment. Twelve pigs, all

2.1

| Study design and endpoints

of similar physical size, met the inclusion criteria.
We performed bench measurements of prosthetic mitral bio-

Between August 2020 and January 2021, 15 Yorkshire pigs under-

prosthesis sizes labeled 25, 27, 29, 31, and 33 mm of the Epic (Ab-

went anatomical evaluation for consideration of enrollment into this

bott, Abbott Park, Illinois), Mosaic (Medtronic, Minneapolis,

study. All of the animals underwent baseline physical screening with

Minnesota), and Mitris Resilia (Edwards Lifesciences, Irvine, Cali-

on‐site veterinary examination at Synchrony Labs (Synchrony Labs

fornia) valves (Table S1). Inner to inner surgical frame dimensions

LLC, Durham, North Carolina). This study was supported by Edwards

were captured at multiple levels of each bioprosthesis. Surgical valve

Lifesciences to Synchrony Labs. The funders had no role in the study

size selection for implantation and comparison for this study was

design, data collection and analysis, decision to publish, or

determined based on grouping of similar internal surgical frame

4656
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bench dimensions, and not manufacturer labeled prosthesis sizing. To

Images, Minnetonka, Minnesota) and Mimics (Materialise, Leuven,

ensure similar anatomical and hemodynamic study conditions for

Belgium) software. All study animals were euthanized and underwent

preclinical evaluation of above surgical valves, pigs with similar sized

on‐site supervised necropsy with cardiac explantation for anatomical

cardiac anatomy (mitral size, left atrial size, left ventricle [LV] func-

evaluation of each surgical bioprosthesis. Given the small sample size,

tion, and LVOT anatomy) were then identified.

descriptive data is presented with no further statistical analysis.

Until the time of valve implantation, the two surgeons were

Continuous and categorical variables are defined as mean and stan-

blinded to which surgical valve was being implanted. Surgical valves

dard deviation; discrete variables are presented as numbers and

were randomized between the surgeons to ensure equal opportunity

percentages.9

at implantation of all three surgical mitral bioprostheses. Echocardiographic and periprocedural CT imaging was performed by the
same imaging physician across all three surgical bioprostheses in all

3 |

RESULTS

phases of device interrogation. As mentioned earlier, mitral bioprostheses studied were the 27‐mm Abbott Epic, the 27‐mm Med-

A total of 15 animals underwent meticulous preclinical CT screening.

tronic Mosaic, and the 25‐mm Edwards Mitris.

All animals were screened to obtain accurate size assessments of
vascular structures, atria, ventricles, myocardium and mitral annulus.
Three animals were excluded due to annular size variations >6%, or

2.3

| Surgical procedure

transeptal crossing height ≤15 mm as evaluated by CT.

Each prosthesis was implanted via a fifth intercostal space left
thoracotomy. After systemic heparinization, the descending aorta

3.1 |

Study population characteristics

and right atrium were cannulated for cardiopulmonary bypass (CPB).
Then, hypothermic systemic perfusion was established at 28°C.

For the 12 pigs, baseline age, body weight, left atrial size as well as

Ventricular fibrillation was induced using a short DC electrical sti-

annular anatomy are depicted in Table 1. There was <6% anatomical

mulus and maintained throughout by hypothermic perfusion.

variation among all study animals. The mean mitral annulus area was

Through a left atriotomy, the anterior mitral valve leaflet was excised

1410.00 ± 133.60 mm2,

and 12–15 subannular pledgeted 2‐0 Ethibond (Ethicon) sutures

28.87 ± 1.93 mm,

were placed circumferentially around the native annulus. Thereafter,

20.53 ± 1.48 mm. All pigs randomized to the Mitris device group had

the sutures were passed through the prosthesis sewing cuff and the

a greater frequency of the circumflex artery coursing closely adjacent

valve was seated. Each suture was secured using titanium Cor‐Knot

to the mitral annulus (4/4) versus 2/4 for the Mosaic, and 1/4 in the

fasteners (LSI Solutions). Saline ventricular pressurization was done

Epic cohort.

and

with
mean

mean

left

transseptal

atrial

height

of

crossing

height

of

to assure proper valve seating. After the left atrium was closed

Baseline hemodynamic and echocardiographic data were similar

partially, the left ventricle was deaired and defibrillated. Ventilation

among all 12 study animals (Table 2). Mitral valve peak gradients

was reestablished and the study animal was rewarmed and weaned

averaged 2.3 ± 0.8 torr, mean gradient 1.1 ± 0.3 torr, and LVOT peak

from CPB. After restoration of normal sinus rhythm and hemody-

gradients averaged 2.2 ± 0.4 torr (mean 1.1 ± 0.2 torr). All study ani-

namic stabilization (similar measurement points), an epicardial 2‐D

mals had normal LV function at baseline (Table 2). By echocardio-

echocardiographic ultrasound study was done to assess prosthesis

graphic evaluation, no animal had underlying pre‐study mitral

transvalvular gradients and ventricular function, as well as to reveal

regurgitation, stenosis, or evidence of left ventricular outflow

any paravalvular leaks. Each animal was then decannulated and he-

obstruction.

mostasis was obtained. The thoracotomy was closed in multiple
layers and then each anesthetized pig was transported to the on‐site
Siemens CT scanner for a postsurgical contrast ECG gated scan to
evaluate prosthetic valve function and anatomic orientation.

3.2 | Comparison of valve prosthesis type: major
safety, technical, and mechanistic endpoints
3.2.1 |

2.4

Imaging measurements

| Data collection and statistics
Postpump acute echocardiographic findings are depicted in Table 2.

Periprocedure (anesthetized but unoperated) multidetector retro-

Among the three studied bioprostheses, in descending order, the 27‐

spectively gated contrast enhanced CT scans were performed on all

mm Epic mitral bioprosthesis had the highest peak/mean mitral gra-

animals. Upon CT scan completion and dataset acquisition, multi-

dient immediately post‐implant, followed by the 27‐mm Mosaic; the

phase cardiac reconstructions of the images were performed at

25‐mm Mitris had the least mitral peak/mean gradient (Table 3).

1.5 mm intervals. Images then were transferred in DICOM (Digital

Doppler velocity indices parameters of all three mitral prostheses

Imaging and Communications in Medicine) format for further eva-

were within normal prosthetic mitral valve function parameters

luation. Postimaging CT processing was performed using Vitrea (Vital

(Table 3).

WANG

|

ET AL.

TABLE 1

4657

Baseline porcine demographic information and CT screening anatomical information
Epic

Mosaic

Mitris

Age at implant (days)

169.8 ± 27.2

165.5 ± 22.8

148.8 ± 7.6

Weight at implant (kg)

88.0 ± 8.95

89.3 ± 6.26

85.0 ± 6.89

Mitral annulus area (sq mm)

1436.75 ± 131.18

1349.0 ± 100.62

1415.25 ± 152.02

Mitral annulus circumference (mm)

139 ± 7.75

133.75 ± 5.38

137.0 ± 7.53

(vs. Mitris 1.45% variation)

(vs. Mitris 2.40% variation)

42.7 ± 1.23

40.35 ± 1.31

(vs. Mitris 2.01% variation)

(vs. Mitris 3.65% variation)

37.35 ± 1.79

38.1 ± 1.0

(vs. Mitris 0.75% variation)

(vs. Mitris 1.24% variation)

43.13 ± 2.79

44.8 ± 1.40

(vs. Mitris 0.30% variation)

(vs Mitris 4.10% variation)

28.35 ± 1.12

29.78 ± 3.17

(vs. Mitris 0.46% variation)

(vs. Mitris 4.46% variation)

Transseptal crossing height (mm)

19.8 ± 1.49

20.85 ± 1.36

(height from a potential mid‐mid transseptal fossa crossing site
to the mitral annulus)

(vs. Mitris 5.55% variation)

(vs. Mitris 0.38% variation)

Frequency of circumflex artery coursing close to mitral annulus

1 out of 4 pigs

2 out of 4 pigs

Mitral annulus commissure to commissure distance (mm)

Mitral annulus anterior to posterior distance (mm)

Left atrium width (mm)

Left atrium height (mm)

41.85 ± 2.72

37.63 ± 2.27

43.0 ± 2.20

28.48 ± 1.41

20.93 ± 1.90

4 out of 4 pigs

Abbreviation: CT, computed tomography.

The mitral bioprosthesis valve opening area was captured by two

bioprosthesis had the greatest strut depth (mean 11.3 ± 0.94 mm).

independent imaging modalities; multiplanar 3D CT reconstruction

This was followed by the 25‐mm Mitris device (8.6 ± 0.56 mm) and

and epicardial echo short‐axis view planimetered at the leaflet tips

the 27‐mm Epic with the shortest protrusion (8.4 ± 0.73 mm)

across all 12 surgical cases (Figure 1). Among the three studied bio-

(Table 4). This sequence remained similar for the antero‐septal

prostheses, in descending order, the 25‐mm Mitris valve by echo-

and posterior struts as well.

cardiographic planimetry had the largest valve opening area
2

2

The depth of ventricular strut length protrusion did not correlate

(2.4 ± 0.15 cm ), followed by the 27‐mm Mosaic (2.04 ± 0.23 cm ),

consistently with postsurgical mitral bioprosthesis LVOT gradients.

and the 27‐mm Epic with smallest valve opening area (1.8 ± 0.27 cm2)

As mentioned, the 27‐mm Mosaic had the greatest LVOT strut pro-

(Figure 1). These findings were consistent and reproducible as well by

trusion with the highest peak/mean LVOT gradient (4.4 ± 1.3)/

the 3D‐CT multiplanar reconstruction post processing evaluations

(1.9 ± 0.5 torr). However, despite having the shorter stent frame

(Table 3 and Figure 1).

compared with the 25‐mm Mitris, the 27‐mm Epic trended toward

We noted that three of the four Epic bioprostheses had para-

having a higher peak/mean LVOT gradient than its counterpart,

valvular annular leak at the anterolateral commissure (Figure 2 and

which had minimal change in this gradient from baseline (Table 4)

Video S1) (Figure 3 paravalvular leak‐red star) postoperatively fol-

(Figure 3).

lowing defibrillation and hemodynamic stabilization. All other postimplantation bioprostheses had no central or paravalvular leaks.

3.3 | Bench measurements: bioprosthesis frame
internal dimensions
3.2.2 | Risk of left ventricular outflow tract
obstruction measures

Among the three manufacturers' valves, measured internal diameters
of new non‐implanted bioprostheses demonstrated significant dif-

There was no clinically significant LVOT obstruction in any study

ferences in valve frame design (Table S1 and Figure S2). For each

cases. After each successful surgical implantation, a 3D multi-

bioprosthesis, the ratio of the internal diameters of the atrial portion

planar CT reconstruction was performed to analyze the depth of

of the device at the level of the sewing ring and ventricular surfaces

the anterolateral and antero‐septal struts within the LVOT

varied (Figure S2). The 27‐mm Epic device demonstrated an atrial

(Figure S1). The anterolateral strut of the 27‐mm Mosaic

valve internal diameter of 22 mm, which decreased to ventricular

4658
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Hemodynamics at time of echocardiographic data capture, including baseline echocardiographic measurements
Epic

Mosaic

Mitris

102.5 ± 13.77

104.0 ± 11.46

103 ± 11.52

(vs. Mitris 0.49% variation)

(vs. Mitris 0.97% variation)

Diastolic blood pressure

57.75 ± 6.65

69.5 ± 7.33

63.75 ± 9.91

Heart rate

73.0 ± 7.44

74.0 ± 8.12

76.25 ± 7.59

(vs. Mitris 4.36% variation)

(vs. Mitris 3.0% variation)

Left ventricle ejection fraction

>55%

>55%

>55%

Mitral valve peak gradient (mmHg)

2.6 ± 0.8

2.1 ± 1.0

2.2 ± 0.7

Mitral valve mean gradient (mmHg)

1.2 ± 0.4

1.0 ± 0.3

1.1 ± 0.3

LVOT peak gradient (mmHg)

2.1 ± 0.3

2.3 ± 0.6

2.3 ± 0.5

LVOT mean gradient (mmHg)

1.0 ± 0.2

1.1 ± 0.3

1.2 ± 0.3

92.5 ± 9.85

91.25 ± 8.81

93 ± 12.65

(vs. Mitris 0.53% variation)

(vs. Mitris 1.9% variation)

Diastolic blood pressure

59.0 ± 7.53

64.75 ± 8.73

62.5 ± 8.96

Heart rate

92.5 ± 11.27

89.8 ± 9.29

89.0 ± 10.55

(vs. Mitris 3.9% variation)

(vs. Mitris 0.89% variation)

Baseline
Systolic blood pressure

Postsurgical valve implant
Systolic blood pressure

TABLE 3
Figure 1)

Surgical valve opening area by echo and CT versus Doppler parameters of prosthetic mitral valve function (see corresponding

Epic (27 mm)

Mosaic (27 mm)

Mitris (25 mm)

Mitral valve peak gradient (mmHg)

9.2 ± 3.7

7.2 ± 4.1

5.1 ± 2.7

Mitral valve mean gradient (mmHg)

4.6 ± 1.9

3.9 ± 2.4

2.6 ± 1.3

Mitral valve peak velocity (cm/s)

148.5 ± 32.54

129.5 ± 39.33

99.1 ± 27.53

Mitral valve VTI (cm)

30.38 ± 5.89

26.65 ± 7.79

21.53 ± 6.59

19.6 ± 2.95

21.08 ± 3.58

14.39 ± 5.73

a

LVOT VTI (cm)
2

1.8 ± 0.27

2.04 ± 0.23

2.4 ± 0.15

a

2

181.5 ± 16.94

206.75 ± 26.6

228.25 ± 12.31

Surgical valve opening area (cm ) by 2D Echo
Surgical valve opening area (mm ) by 3D multiplanar CT

Abbreviation: CT, computed tomography.
a

Surgical valve opening area defined as planimetry area at level of bioprosthetic leaflet tips during maximal valve opening.

internal dimensions of 19 mm. The 27‐mm Mosaic demonstrated similar internal measurements (22 mm) at the atrial portion and de-

3.4 | Surgical bioprosthesis strut design in the left
ventricular outflow tract

creased to 22 × 21 mm in the ventricular portions. The 25‐mm Mitris
internal dimensions were similar within the atrial and ventricular

Among the three types of surgical mitral bioprostheses, there was

portions of the valve frame design.

variation in strut length, strut width, and aortic outflow tract diameter

Bench‐top true anatomical opening measurements of the Mitris,

opening between struts depending on strut location (Table S2). At the

Epic, and Mosaic valves did not match manufacturer‐labeled nu-

position of the aortic outflow tract, the 27‐mm Mosaic had the

merical designations (Table S1). For the 27‐mm Epic and Mosaic

longest and widest strut (14‐mm length, 12‐mm width), followed by

valves, maximum and minimum dimensions were 22 mm. Similar

the 27‐mm Epic (8‐mm length, 11‐mm width) (Table S2). The 25‐mm

measurements for the 25‐mm Mitris device were 23 mm (internal

Mitris had the shortest and narrowest surgical strut (7‐mm length,

diameter dimension).

4‐mm width). The distance between the anterolateral (“left fibrinous

WANG
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F I G U R E 1 Maximal surgical valve opening area of mitral bioprostheses' leaflets. (A) shows the epicardial 2D echocardiographic planimetry
measurement of the surgical mitral bioprosthesis leaflet tips at maximal mid‐end diastolic opening by type of bioprosthesis with trend in
ascending order, 27‐mm Epic with the smallest surgical valve opening area, followed by the 27‐mm Mosaic and largest in the 25‐mm Mitris. (B)
demonstrates the corresponding maximal mid‐end diastolic mitral bioprosthesis surgical valve opening area leaflet tip planimetry by multiplanar
3D‐CT evaluation with similar trends. CT, computed tomography
F I G U R E 2 Paravalvular leak in anterolateral
trigone of Epic mitral bioprostheses (Video S1).
Three of the four Epic mitral bioprostheses were
noted to have a paravalvular leak at the
anterolateral commissure of the mitral prothesis
sewing cuff postcardiopulmonary bypass
epicardial echocardiographic interrogation

trigone”) and anteroseptal (“right fibrinous trigone”) struts of the

anteroseptal

bioprostheses oriented to the aortic outflow tract varied depending

respectively.

prosthesis

struts,

measuring

14

and

17 mm,

on the height of the surgical strut protrusion within the aortic outflow
tract (Table S2 and Figure S3). At the level of the sewing ring, the 27‐
mm Epic device had the smallest aortic outflow tract opening be-

4 |

D IS CU SS IO N

tween its anterolateral and anteroseptal struts, measuring 10 mm, as
compared to its most ventricular portion measuring 15 mm

Porcine models have been used extensively for evaluation of pros-

(Figure S3). The 27‐mm Mosaic had a larger aortic outflow tract

thetic valves.10–12 This is the first preclinical head‐to‐head evalua-

distance between its struts at the level of the sewing ring, 12 mm, as

tion, under controlled anatomic and hemodynamic conditions, of

compared to its most distal strut markers, 16 mm. The 25‐mm Mitris

three comparable surgical mitral bioprostheses. This was a fully in-

had the largest aortic outflow opening between its anterolateral and

dependent, physician‐designed and ‐executed scientific early

4660
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F I G U R E 3 Differences in bioprosthesis strut design. The width of mitral bioprosthesis strut design varies among similar manufacturer
labeling “sized” devices. (A) Pictured in the front is the Mitris bioprosthesis with the narrowest strut width, followed by the Epic with the widest
strut width, and the Mosaic with the longer strut, but falling in between the Mitris and Epic in strut width. (B) Surgical prosthesis strut length has
been long considered a risk factor for turbulent flow and outflow obstruction in the aorta. Side‐by‐side comparison of the Mosaic, Epic and
Mitris bioprostheses demonstrate an atrial lift mechanism (yellow arrow) in the anterior arch design (dash bracket) of the Mitris valve that
diminishes the amount of strut protruding(dotted yellow arrow) into the aorta despite overall length of the struts

Epic (27 mm)

Mosaic (27 mm)

Mitris (25 mm)

Anteroseptal strut protrusion in LV by
CT (mm)

8.2 ± 0.12

11.9 ± 1.03

8.6 ± 0.65

Anterolateral strut protrusion in LV by
CT (mm)

8.4 ± 0.73

11.3 ± 0.94

8.6 ± 0.56

Posterior strut protrusion in LV by CT (mm)

9.0 ± 0.87

12.4 ± 0.47

10.0 ± 0.37

LVOT peak gradient

3.4 ± 1.3

4.4 ± 1.3

2.1 ± 1.1

LVOT mean gradient

1.7 ± 0.6

1.9 ± 0.5

1.0 ± 0.6

TABLE 4

Struts versus hemodynamics

Note: Postsurgical mitral bioprosthesis LVOT obstruction risk evaluation. Postsurgical CT
measurements of each bioprosthesis' degree of strut protrusion in the aorta were measured. Shown in
Row 4 is the corresponding epicardial echocardiographic LVOT peak to mean gradient for each
bioprosthesis subgroup.
Abbreviations: CT, computed tomography; LV: left ventricle, LVOT: left ventricular outflow tract.

feasibility comparison study of multiple current mitral valve

largest surgical valve leaflet tip opening area, and the smallest peak/

bioprostheses.

mean mitral gradient, (5.1 ± 2.7 torr)/(2.6 ± 1.3 torr), compared with

Here, we show that there was a strong connection between (1)

the Epic and Mosaic bioprostheses. Among the three surgical mitral

SOA and mitral peak/mean gradient, (2) surgical internal frame design

bioprostheses, the 27‐mm Mosaic had the greatest length and

and mitral peak/mean gradient, and (3) width of surgical strut in

greatest width of strut protrusion into the LVOT; and highest

addition to length of surgical strut for LVOT peak gradients. At the

peak LVOT gradient (4.4 ± 1.3 torr). The 27‐mm Epic and 25‐mm

level of the mitral annulus, the 27‐mm Epic had the smallest surgical

Mitris devices had comparable strut protrusion lengths into the

internal frame dimensions, the smallest surgical valve leaflet tip

LVOT (Table 4). However, the 27‐mm Epic had wider strut dimen-

opening area, the most tapered internal surgical frame design (di-

sions (Table S2), and smaller distance between the struts oriented

mensions extending from the level of the mitral annulus to the level

toward the aortic outflow tract, and a higher peak LVOT gradient

of the distal struts); and the highest peak/mean mitral gradient

(3.4 ± 1.3 torr) than the similar length 25‐mm Mitris (2.06 ± 1.05 torr).

(9.2 ± 3.7)/(4.6 ± 1.9 torr). The 27‐mm Mosaic had similar internal

These data suggest that among similar sized mitral bioprostheses,

frame dimensions to the 27‐mm Epic, less tapered internal surgical

there is significant variation in bioprosthetic valve form and

frame design at the level of the distal struts, and a larger SOA. The

function.

27‐mm Mosaic had a smaller peak/mean mitral gradient, (7.2 ± 4.1)/

Selection of prosthetic mitral valve remains difficult.3 Labeled

(3.9 ± 2.4 torr), than the 27‐mm Epic. The 25‐mm Mitris had a larger

prosthetic valve sizing is not standardized.4 Internal diameters of

internal frame dimension, with a nontapered surgical frame design,

surgical valves vary significantly depending on manufacturer, not only
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at the level of the tissue annulus, but additionally at the level of the

clinical studies. The importance of this study demonstrates the need

ventricular struts.3 There are conflicting reports on rates of structural

for a pivotal trial with larger number of patients and longer period of

valve deterioration, reoperation, and methodologies on how to assess

follow‐up to thoroughly assess the potential impact of surgical mitral

hemodynamic function between bovine pericardial and porcine

bioprosthesis design on bioprosthesis function. Given the small

stented prosthetic mitral replacement.13–17

number of animals in this pilot study, all results should be interpreted

Given the heterogeneity of mitral bioprosthesis valve design, there
is a need for scientific standardization and validation of mitral pros-

as hypothesis generating. Larger studies will be necessary to evaluate
for long‐term clinical outcomes.

theses' sizing for human clinical implantation. In the clinical context,
mitral bioprosthesis valve dysfunction is felt to warrant clinical evaluation for potential future transcatheter mitral valve‐in‐valve re-

5 |

CONCLUSIONS

placement (TMVR) therapies once mitral bioprostheses fall to a mitral
valve area ≤1.5 cm2. A difference of almost 0.6 cm2 in SOA in a freshly

Rigorous scientific evaluation of surgical mitral bioprostheses is ne-

implanted surgical device without the presence of pannus ingrowth or

cessary for patient safety. Based on these results, we would advise

calcification may account for why some mitral bioprostheses are more

caution when evaluating manufacturers' advertising. Implications of

commonly associated with need for reoperation or TMVR valve in

this study demonstrate a critical need for standardization and sci-

valve. Additionally, the impact of varying surgical strut design, surgical

entific evaluation of surgical mitral bioprostheses to ensure optimal

frame shapes, and width between surgical struts at the anterolateral

outcomes for clinical human implantation.

and anteroseptal trigones may impact the efficacy of potential future
transcatheter LVOT modification techniques such as laceration of the
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